



E-ISSN: 2706-9575
P-ISSN: 2706-9567
IJARM 2023; 5(3): 117-122
Received: 07-06-2023
Accepted: 16-07-2023

Salma O Alshamsi
Adult Infectious Diseases,
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Fatema Abdulkarim
Adult Pulmonary Diseases,
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Ali Alzaidy
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Hassan Ahmed
Adult Infectious Diseases,
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Samya Javid
Adult Infectious Diseases,
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Eman Ibrahim Elzain
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Mohamed Awad Mahmoud Ahmed
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Irum Zahid Ansari
Department of Paediatrics, Latifah
Hospital, Dubai Health Authority,
Dubai UAE

Laila M AIDabal MD
Adult Infectious Diseases,
Department of Medicine, Rashid
Hospital, Dubai Health Authority,
Dubai UAE

Pramod Chhabrani
Department of Internal Medicine,
Al Kuwait Hospital, Emirates
Health Services, Dubai, UAE

Corresponding Author:
Pramod Chhabrani
Department of Internal Medicine,
Al Kuwait Hospital, Emirates
Health Services, Dubai, UAE

Clinical characteristics and outcomes in adult patients with COVID-19 infection admitted to a Tertiary Care Hospital in Dubai, United Arab Emirates

Salma O Alshamsi, Fatema Abdulkarim, Ali Alzaidy, Hassan Ahmed, Samya Javid, Eman Ibrahim Elzain, Mohamed Awad Mahmoud Ahmed, Irum Zahid Ansari, Laila M AIDabal MD and Pramod Chhabrani

DOI: <https://doi.org/10.22271/27069567.2023.v5.i3b.509>

Abstract

SARS-CoV-2 is a novel coronavirus that was responsible for the global COVID-19 pandemic. Our hospital was one of the largest hospitals in the UAE to admit and manage patients with this novel infection since the beginning of the pandemic in the country. The main objective of this paper was to review clinical characteristics and outcomes in adult patients with COVID-19 infection admitted to our hospital.

Methods: A single center retrospective observational study of 684 adult patients with confirmed COVID-19 infection admitted to a tertiary care hospital in Dubai in 2020 from 28/1/2020 until 13/05/2020. A select of clinical, radiological, epidemiological and Laboratory data was analyzed in relation to clinical presentation and disease outcome including ICU admission and overall mortality. Only patients with confirmed COVID-19 infection based on positive nasopharyngeal/throat swabs for SARS-CoV-2 virus on Real Time PCR (RT-PCR) were included in final analysis.

Results: Of the total 684 adult patients, 90.9% were males (n=622) with a mean age of 44.43 years (range of 66 years, from 15 to 81 years). Significant number of patients had co-morbidities as 177 (25.9%) patients had diabetes, 121 (17.7%) had hypertension, 28 (4.1%) had heart disease and 7 (1.0%) had renal disease. The most common presenting symptoms were fever (87.4%) cough (73.5%), shortness of breath (35.1 %), URTI (18.6%), and Diarrhea (8%). The clinical conditions among these 99 patients included upper respiratory tract infection (47.5%), abnormal chest X-ray, lymphopenia, high inflammatory markers a fifth (21%) of patients had moderate pneumonia, while 7% had severe pneumonia with 22.2% requiring admission to the intensive care unit and 12.1% died. Late presentation with severe disease, an abnormal chest X-ray, lymphopenia, high inflammatory markers (C- reactive protein, ferritin and procalcitonin), and end organ damage (high creatinine or high aspartate aminotransferase) were predictors for admission to critical care unit or died.

Conclusion: Older patients (age > 50 years), those with High BMI (>27), high LDH, hypertension, diabetes, SOB, High urea, presence of pneumonia, were associated significantly with a higher risk of ICU admission and higher mortality rates.

Keywords: COVID-19, UAE, Dubai, ICU, outcomes, clinical characteristics

Introduction

SARS-CoV-2 virus resulting in COVID-19 infection, was declared as a global pandemic by World Health Organization on 11 March 2020 [1]. The infection had huge medical and financial consequences affecting the whole world. It infected hundreds of millions globally and resulted in millions of lives lost secondary to the infection or its complications. Coronaviruses (CoVs) are a large family of viruses that cause diseases in mammals and birds and are responsible for severe respiratory illnesses such as the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in humans [2]. First cases of SARS-CoV-2 infection were diagnosed in the city of Wuhan, China, by the end of December 2019 and they were initially thought to be linked to a local food market in the city. On January 29, 2020, the United Arab Emirates Ministry of Health and Prevention announced the diagnosis of the first COVID-19 infection in the UAE for members of a family arriving from the Chinese city of Wuhan [3]. Following that family cluster, positive cases continued to be detected as an imported infection; however, as in other countries regionally and globally, it did not take long for local transmission of COVID-19 to be well established [4].

So, during the first wave and as of December 27, 2020, UAE had a COVID-19 cases recovery rate of 89% and recorded 669 deaths from COVID-19 with an overall case-fatality of 0.3% since the beginning of the pandemic [5]. The UAE led in testing and the number of tests conducted per one thousand people is highest in the United Arab Emirates [6]. This helped a lot in early case identification, isolation and quarantine measures and contributed significantly to the cumulative initiatives and efforts to contain the pandemic locally and globally. Having that said, the pandemic continued and there were several subsequent waves resulting in hundreds of millions of COVID-19 cases diagnosed globally with a death toll reaching 6,542,894 lost lives as of September 2022 [7].

The spectrum of clinical manifestations of COVID-19 infection ranges from asymptomatic/subclinical infection to mild-moderate-severe infection, with some patients requiring intensive care admission and even mechanical ventilation. Data from several clinical studies revealed that nearly 40% of COVID-19 infections are asymptomatic [8, 9]. This point is important from epidemiological and infection control standpoints.

The most commonly reported symptoms are cough, fever, fatigue, myalgia, headache, loss of smell, nasal obstruction, asthenia, rhinorrhea, gustatory and olfactory dysfunction, and sore throat [10].

Patients with severe COVID-19 can present with dyspnea and hypoxia, with chest imaging revealing more than 50% involvement of the lungs. Patients with critical COVID-19 infection will have a severe respiratory failure with or without multi organ failure and shock. Regarding markers of severe infection, there have been several predictors and risk factors identified in different studies and patient populations. Among those factors, the most reported were age, Body Mass Index, SOFA score on admission, high inflammatory markers, and underlying Diabetes Mellitus [11, 12].

Our study aimed to review the clinical characteristics and outcome of adult patients with COVID-19 infection admitted to a tertiary care hospital in Dubai in the first wave of the pandemic. The review also studied the profiles of patients admitted to the Intensive Care Unit over study period and looked into important prognostic factors.

Methods

Study design and setting

A retrospective observational study was conducted at

Rashid hospital, Dubai, UAE, one of the largest tertiary care hospitals and COVID-19 isolation and management facilities across the country during the pandemic.

684 laboratory-confirmed COVID-19 adult patients were admitted to our hospital over the first few months of the pandemic between 28 January to 13 May 2020. Only patients with confirmed COVID-19 infection based on positive nasopharyngeal and or throat swabs for SARS-CoV-2 virus on Real Time PCR (RT-PCR) were included in the study. UAE National COVID-19 management guidelines were used for case definitions, diagnostic work up and active management plan. All patients included in the study had baseline blood tests and radiological workup performed as per National Guidelines recommendations.

Data collection

Patients data were collected from Hospital's Electronic Medical Record (EMR) system. Data included the patient's demographics, age, gender, nationality, Body Mass Index, presenting symptoms, baseline labs, and chest imaging findings. In addition, other variables like medical comorbidities, Intensive Care Unit admission, need for Oxygen therapy and over all outcome were also included in final data analysis.

Ethical approval

The study was approved by the Dubai Health Authority and hospital ethical committees. No potential risk to the patients was anticipated.

Statistical analysis

Minitab 17 was used as the statistical analysis software tool. Data analysis was done using Chi-square and 2 sample proportions methods. Descriptive statistics to describe data were used, and the level of statistical significance was set at 0.05.

Results

Demographics and Clinical Characteristics

This study included 684 patients with an average age of 44.43 years from different nationalities. As observed during the first wave of COVID-19 infection, there was significant male predominance, and in our patients, there was 9:1 male to female ratio. With the known country's demographics, patients from Asian origin; mainly India (38.3%), Pakistan (20.9%) & Bangladesh (11.7) constituted more than two thirds of overall study sample.

Table 1: Demographics of study data

| Characteristics, n(%), unless specified otherwise | All (N = 684) | Not Admitted to ICU (n=567(82.9%)) | Admitted to ICU (n = 117(17.1%)) | P-value |
|---------------------------------------------------|----------------|------------------------------------|----------------------------------|--------------|
| Demographics | | | | |
| Age, Mean (SD) | 44.43 (±11.37) | 43.26 (±10.88) | 50.08 (±12.02) | 0.048 |
| Nationality | | | | |
| India | 262(38.3%) | 209(36.9%) | 53(45.3%) | 0.827 |
| Pakistan | 143(20.9%) | 116(20.5%) | 27(23.1%) | 0.476 |
| Bangladesh | 80(11.7%) | 71(12.5%) | 9(7.7%) | 0.128 |
| Others | 199(29.1%) | 171(30.2%) | 28(23.9%) | 0.415 |
| Gender | | | | |
| Male | 622(90.9%) | 513(90.5%) | 109(93.2%) | 0.912 |
| Female | 62(9.1%) | 54(9.5%) | 8(6.8%) | 0.701 |
| Symptoms | | | | |
| Fever | 598(87.4%) | 493(86.9%) | 105(89.7%) | 1.000 |
| Cough | 503(73.5%) | 409(72.1%) | 94(80.3%) | 0.081 |

| | | | | |
|-------------------------------|------------|------------|------------|--------------|
| SOB | 240(35.1%) | 161(28.4%) | 79(67.5%) | 0.012 |
| URTI | 127(18.6%) | 111(19.6%) | 16(13.7%) | 0.196 |
| Diarrhea | 55(8.0%) | 47(8.3%) | 8(6.8%) | 0.561 |
| Other Symptoms | 266(38.9%) | 228(40.2%) | 38(32.5%) | 0.602 |
| Abnormal CXR | 545(79.9%) | 132(23.3%) | 7(6.0%) | 0.001 |
| Unilateral opacification | 110(16.1%) | 101(17.8%) | 9(7.7%) | 0.041 |
| Bilateral opacification | 428(62.6%) | 327(57.7%) | 101(86.3%) | 0.046 |
| Comorbidities | | | | |
| DM | 177(25.9%) | 125(22.0%) | 52(44.4%) | 0.025 |
| HTN | 121(17.7%) | 90(15.9%) | 31(26.5%) | 0.048 |
| Heart Disease | 28(4.1%) | 21(3.7%) | 7(6.0%) | 0.149 |
| Renal Disease | 7(1.0%) | 3(0.5%) | 4(3.4%) | 0.011 |
| O2 therapy received | 315(46.1%) | 216(38.1%) | 99(84.6%) | 0.00 |
| Outcome | | | | |
| Discharged from our hospital | 110(16.1%) | 82(14.5%) | 28(23.9%) | 0.103 |
| Transferred to other facility | 484(70.7%) | 479(48.4%) | 5(4.3%) | 0.00 |
| Deceased | 75(11.0%) | 5(0.9%) | 70(59.8%) | 0.00 |

Regarding patient symptomatology, fever was reported and documented in almost 90% of patients, followed by a cough which was reported by 73.5% of patients. Less frequent symptoms among our cohort was Upper Respiratory tract complaints and diarrhea. This was compatible with findings from other studies during the first wave [13, 14, 15].

One third of admitted patients has shortness of breath and this matched the higher oxygen requirements and worse chest X ray findings and subsequent ICU admission and higher mortality rates.

There was an important observation regarding BMI and ICU admission; so, patients with BMI above 29 Kg/m² had higher risk of intubation and mechanical ventilation. The same observation was made by other groups as well [16, 17].

Laboratory and radiological findings

Baseline hematology panel was normal in almost all patients upon day one of admission. Excluding patients with underlying renal diseases, almost all patients had normal baseline renal and electrolytes profiles. And similar to other studies which showed mild rise in transaminases, there was mild rise in ALT in majority of patients [18]. Our patients had normal bilirubin as well. There was an observed acute rise in globulin signifying the intense immune response and rapid formation of antibodies during acute infection.

In our study, higher levels of urea, LDH and CRP and were associated with risk for ICU admission, and they reflected more severe disease and possible concomitant bacterial pneumonia.

LDH for ICU patients has an average of 467 U/L, significantly higher than those not admitted to ICU.

Mean CRP level among all admitted patients was 76.9 mg /L and the mean for ICU admitted patients was 154.4 mg/l (p- values 0.039). CRP levels above 70 mg/L was taken as one marker of severe infection and guided the use of steroids and other immune-modulating therapy [19, 20, 21].

Almost 80% of patients had abnormal chest X-rays and the presence of bilateral pulmonary opacifications was found to be associated with higher disease severity score and higher rate of ICU admission.

Clinical outcomes

Figure 1 outlines the clinical outcomes of the cohort including overall mortality. And in alignment with clinical and field observations from other COVID-19 managing centers and countries in the first wave of the pandemic; there was high mortality among admitted patients. Among our cohort of admitted patients; the overall mortality was 11%. This was significantly higher in patients admitted to ICU and reached almost 60% of patients (59.8% of the patients in ICU) in comparison to non-ICU patient group where it was below 1% (0.9% of non- ICU patients). Factors associated with higher mortality among ICU-admitted patients included DM (p = 0.025), age above 50 years (p = 0.048), high CRP (p = 0.039) and high Urea levels (p = 0.016).

Table 2: Patient lab results classified based on ICU admission

| Characteristics | All (N = 684) | Not Admitted to ICU (n=567(82.9%)) | Admitted to ICU (n = 117(17.1%)) | P-value |
|------------------------------|-----------------|------------------------------------|----------------------------------|---------|
| BMI, Mean (SD), | 27.38(±4908) | 26.92(±4.666) | 29.66(±5.413) | 0.049 |
| WBC, Mean (SD), /ul | 7.230(±2.962) | 6.976(±2.773) | 8.461(±3.508) | 0.163 |
| HB, Mean (SD), g/dl | 14.16(±1.353) | 14.23(±1.330) | 13.84(±1.421) | 0.401 |
| PLT, Mean (SD), ul | 217.5(±74.82) | 215.7(±73.83) | 226.3(±79.17) | 0.356 |
| Lymphocyte, Mean (SD), /ul | 1.273(±0.960) | 1.315(±0.9448) | 1.068(1.010) | 0.763 |
| Urea, Mean (SD), mg/dl | 26.75(±12.18) | 25.74(±10.84) | 31.62(±16.47) | 0.016 |
| Creatinine, Mean (SD), mg/dl | 0.9385(±0.3339) | 0.9175(±0.2875) | 1.040(±0.4903) | 0.056 |
| ALT, Mean (SD), u/l | 38.73(±21.99) | 38.22(±21.85) | 41.21(±22.55) | 0.415 |
| Bilirubin, Mean (SD), mg/dl | 0.5638(0.2866) | 0.5571(±0.2960) | 0.5961(±0.2338) | 0.156 |
| Globulin, Mean (SD), g/dl | 3.745(±0.5207) | 3.711(0.5220) | 3.912(±0.4830) | 0.231 |
| LDH, Mean (SD), u/l | 326.8(±145.5) | 296.6(±121.8) | 467.0(±164.0) | 0.001 |
| CRP, Mean (SD), mg/L | 76.90(±84.27) | 60.77(±68.14) | 154.5(±108.3) | 0.039 |
| LOST, Mean (SD), | 11.59(±13.01) | 8.982(±9.085) | 25.17(±20.08) | 0.001 |




Fig 1: Comparison of Clinical Outcome of Covid-19 patients based on ICU admission

In this study, we describe the clinical characteristics, outcomes, and laboratory findings of confirmed COVID-19 patients admitted to a tertiary care hospital in Dubai in the first wave of the pandemic.

Matching with other epidemiological data from other countries, there was significant male predominance in the first wave and our study population was mostly presented by middle-aged men from non-UAE nationality. This is well explained by the country's demographic constitution where almost 90% of the resident population are non-UAE nationals.

Diabetes Mellitus and obesity were the most important factors associated with COVID-19 clinical progression, ICU admission and final disease outcome. Other authors have studied in details COVID-19 prognostic factors and data from several papers has been consistent with this observation [22, 23].

Age on itself was another risk factor for disease progression and patients above the age of 50 years were at higher risk of severe infection and ICU admission. These patients will suffer from other medical comorbidities that increase their risk of ICU admission [24]. This was observed by other researchers as well [25, 26, 27]. However, patients were older in other studies in comparison to our cohort.

Shortness of breath in the setting of COVID-19 infection can signify severe COVID-19 pneumonia resulting ultimately in ICU admission. Zhao *et al.* looked into clinical presentation of patients admitted to the ICU patients and found that those who presented with SOB were more likely to require higher levels of care (78.5% vs. 64.8%, $p = 0.001$) [28].

Chest imaging is an important diagnostic and prognostic tool in the setting of COVID-19 pneumonia. There have been several publications in this field starting from early group of infected patients in Wuhan. Studies have shown that patients with bilateral pulmonary opacifications were at higher risk of ICU admission and worse outcome. Patients with bilateral pneumonia also had higher oxygen requirements [18, 29-33].

Our study also pointed to other patient-related factors associated with higher risk of ICU admission like Diabetes Mellitus; higher body mass index; dyslipidemia, and Hypertension [34, 35].

Among tested biomarkers based on our National COVID-19 management guidelines; LDH was significantly higher in more sick patients who ended up in the ICU. This finding was also observed by other researchers in other studies where elevated LDH levels on admission can be considered an independent risk factor for the mortality and severity of COVID-19 [36, 37]. It is not specific to COVID-19 infection and higher levels reflects more systemic inflammation and higher disease burden.

Other inflammatory markers tested in our patients included CRP and procalcitonin. Indeed, we used them to stratify patients with concomitant bacterial pneumonia and reduce the use of antibiotics as part of active Antimicrobial stewardship activities during the pandemic. The presence of high CRP alone was not an indicator to start antibiotics and was taken into the context of more severe COVID-19 infection.

Other studies also looked into clinical significance of CRP and PCT as prognostic markers, mainly in patients with pneumonia [38, 39].

Study Limitation

This study has several limitations. The retrospective data collection design did not allow the capture of more detailed information; follow-up process was limited and not well structured in the first wave; some data were missing, particularly in the non-ICU patients, in addition, small sample size and single center experience could have affected the statistical significance of important risk factors and clinical parameters.

Conclusion

The United Arab Emirates took the lead in controlling the pandemic locally and globally from different aspects and proved its success in containing the damage. Among our admitted patients in the first wave; fever and respiratory complaints predominated the symptomatology and majority of patient had abnormal chest X ray signifying COVID-19 pneumonia. Some prognostic markers were associated with higher risk of ICU admission including some non-modifiable factors like age, gender, BMI and underlying comorbidities and overall mortality rates were high among patients admitted to the ICU. This is expected in the setting

of novel virus with multi-systemic presentation in the lack of effective specific anti-viral therapy and safe vaccines during the first wave of the pandemic.

Conflict of Interest

The authors declare no conflict of interest.

Funding

This research group did not receive grants from any public, commercial, or not-for-profit funding agencies.

Ethical Approval

Dubai Health Authority and hospital ethical committees approved the study. No potential risk to the patients was anticipated.

Data Availability Statement

Data used and/or analyzed during this study was extracted from a patient data system in a tertiary care hospital in Dubai.

References

1. What is COVID-19 and how is it spread? [Internet]. www.gavi.org. [cited 2022 Aug 4]. Available from: https://www.gavi.org/vaccineswork/what-is-covid-19-and-how-does-spread?gclid=CjwKCAjw14uVBhBEEiwAaufYx0JMBAcDgKMW8Dy-LT7LFV3WHaCJ5UtNswA77Hkdegk2zTXQGT85hxoC-dMQAvD_BwE
2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *Journal of Medical Virology*. 2020;92(4):418-423. <https://doi.org/10.1002/jmv.25681>
3. Abed Alah M, Abdeen S, Kehyayan V. The first few cases and fatalities of Corona Virus Disease 2019 (COVID-19) in the Eastern Mediterranean Region of the World Health Organization: A rapid review. *Journal of Infection and Public Health*. 2020;13(10):1367-1372. <https://doi.org/10.1016/j.jiph.2020.06.009>
4. Cheng C, Barceló J, Hartnett AS, Kubinec R, Messerschmidt L. COVID-19 Government Response Event Dataset (Corona Net v.1.0). *Nature Human Behaviour*. 2020;4(7):756-768. <https://doi.org/10.1038/s41562-020-0909-7>
5. Future Internet. United Arab Emirates Ministry of Health and Prevention [Internet]. Ministry of Health and Prevention - UAE. 2020 [cited 2020 Dec 12]. Available from: <https://www.mohap.gov.ae/en/MediaCenter/News/Pages/2365.aspx>.
6. Wang ZH, Shu C, Ran X, Xie CH, Zhang L. Critically Ill Patients with Coronavirus Disease 2019 in a Designated ICU: Clinical Features and Predictors for Mortality. *Risk Management and Healthcare Policy*. 2020;13:833-845. <https://doi.org/10.2147/rmhp.s263095>
7. COVID Live - Coronavirus Statistics – Worldometer; c2022. Worldometers. <https://www.worldometers.info/coronavirus/>
8. Clinical characteristics of COVID-19 [Internet]. European Centre for Disease Prevention and Control. Available from: <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical>
9. Radwan E, Radwan A, Radwan W. Challenges Facing Older Adults during the COVID-19 Outbreak. *European Journal of Environment and Public Health*. 2020;5(1):em0059.
10. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. *Revista de Saúde Pública*. 2020 Jul 10;54:60.
11. Ghosn M, Attallah N, Badr M, Abdallah K, De Oliveira B, Nadeem A, *et al*. Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes. *Journal of Clinical Medicine*. 2021;10(6):1217.
12. Dusseaux MM, Antoun S, Grigioni S, Béduneau G, Carpentier D, Girault C, *et al*. Skeletal muscle mass and adipose tissue alteration in critically ill patients. *PLOS ONE*. 2019;14(6):e0216991. <https://doi.org/10.1371/journal.pone.0216991>
13. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. *Critical reviews in clinical laboratory sciences*. 2020;57(6):389-399.
14. Alsayer RM, Alsharif HM, Al Baadani AM, Kalam KA. Clinical and epidemiological characteristics of COVID-19 mortality in Saudi Arabia. *Saudi Medical Journal*. 2021;42(10):1083.
15. Alahmari AA, Khan AA, Elganainy A, Almohammadi EL, Hakawi AM, Assiri AM, *et al*. Epidemiological and clinical features of COVID-19 patients in Saudi Arabia. *Journal of Infection and Public Health*. 2021;14(4):437-443.
16. Hussain A, Mahawar K, Xia Z, Yang W, Shamsi EH. Retracted: Obesity and mortality of COVID-19. *Meta-analysis. Obesity research & clinical practice*. 2020;14(4):295-300.
17. Mahamat-Saleh Y, Fiolet T, Rebeaud ME, Mulot M, Guihur A, El Fatouhi D, *et al*. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. *BMJ open*. 2021;11(10):e052777.
18. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, *et al*. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *European journal of nuclear medicine and molecular imaging*. 2020;47(5):1275-1280.
19. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. *Journal of hepatology*. 2020;73(5):1231-1240.
20. Amin M. COVID-19 and the liver: overview. *European journal of gastroenterology & hepatology*. 2021;33(3):309-311. <https://doi.org/10.1097/MEG.0000000000001808>
21. Ahlström B, Frithiof R, Hultström M, Larsson I, Strandberg G, Lipcsey M. The swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. *Acta Anaesthesiologica Scandinavica*. 2021 Feb 8;65(4):525-33.
22. Pugliese G, Vitale M, Resi V, Orsi E. Is diabetes mellitus a risk factor for CoronaVirus Disease 19 (COVID-19)? *Acta Diabetologica* [Internet]. 2020 Aug 31 [cited 2020 Oct 27];1-11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456750/>
23. Auvinen R, Nohynek H, Syrjänen R, Ollgren J, Kerttula T, Mäntylä J, *et al*. Comparison of the clinical

- characteristics and outcomes of hospitalized adult COVID-19 and influenza patients – a prospective observational study. *Infectious Diseases*. 2020;53(2):111-121. <https://doi.org/10.1080/23744235.2020.1840623>
24. Ali AM, Kunugi H. Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19). *International Journal of Environmental Research and Public Health*. 2021;18(5):2772. <https://doi.org/10.3390/ijerph18052772>
 25. Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, *et al*. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. *The Lancet*. 2022;399(10334):1513-1536.
 26. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DA, Azman AS, Paireau J, *et al*. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2021;590(7844):140-145.
 27. Zhao Z, Chen A, Hou W, Graham JM, Li H, Richman PS, *et al*. Prediction model and risk scores of ICU admission and mortality in COVID-19. *Adrish M, editor. PLOS ONE*. 2020 Jul 30;15(7):e0236618.
 28. WAM. UAE announces first case of new coronavirus [Internet]. *wam*. WAM; c2020. Available from: <https://wam.ae/en/details/1395302819532>
 29. Nguyen-Van-Tam JS, Openshaw PJM, Hashim A, Gadd EM, Lim WS, Semple MG, *et al*. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). *Thorax*. 2010;65(7):645-651. <https://doi.org/10.1136/thx.2010.135210>
 30. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *Journal of Medical Virology*. 2020;92(11):2409-2411. <https://doi.org/10.1002/jmv.26097>
 31. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, *et al*. C-reactive protein and clinical outcomes in patients with COVID-19. *European heart journal*. 2021;42(23):2270-2279.
 32. Wong HYF, Lam HYS, Fong AHT, Leung ST, Chin TWY, Lo CSY, *et al*. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. *Radiology*. 2020;296(2):E72-E78.
 33. Garbati MA, Fagbo SF, Fang VJ, Skakni L, Joseph M, Wani TA, *et al*. A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. *PLOS ONE*. 2016;11(11):e0165978.
 34. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. *Revista de Saúde Pública*. 2020;54:60. <https://doi.org/10.11606/s1518-8787.2020054002481>
 35. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, *et al*. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *Journal of Internal Medicine*. 2020;288(3):335-344. <https://doi.org/10.1111/joim.13089>
 36. Hafidh K, Abbas S, Khan A, Kazmi T, Nazir Z, Aldaham T. The Clinical Characteristics and Outcomes of COVID-19 Infections in Patients with Diabetes at a Tertiary Care Center in the UAE. *Dubai Diabetes and Endocrinology Journal*. 2020;26(4):158-163. <https://doi.org/10.1159/000512232>
 37. Rashid Alteneiji H, Ahmed V, Saboor S. A qualitative approach to investigate emergency preparedness state for the built environment in the UAE. *Engineering, Construction and Architectural Management*. 2020;28(7):2005-2022. <https://doi.org/10.1108/ecam-05-2020-0296>.
 38. Sunjaya AP, A Wamae Ildia SM, Di Tanna GL, Jenkins C. Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. *Journal of Asthma*. 2021;59(5):866-879.

How to Cite This Article

Alshamsi SO, Abdulkarim F, Alzaidy A, Ahmed H, Javid S, Elzain EI, *et al*. Clinical characteristics and outcomes in adult patients with COVID-19 infection admitted to a Tertiary Care Hospital in Dubai, United Arab Emirates. *International Journal of Advanced Research in Medicine*. 2023;5(3):117-122.

Creative Commons (CC) License

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.